Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein (Q33267448)

24 July 2017

title

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein (English)

1 reference

24 July 2017

0 references

F A de Jong

1

1 reference

24 July 2017

T J Scott-Horton

2

1 reference

24 July 2017

D L Kroetz

3

1 reference

24 July 2017

H L McLeod

4

1 reference

24 July 2017

L E Friberg

5

1 reference

24 July 2017

R H Mathijssen

6

1 reference

24 July 2017

J Verweij

7

1 reference

24 July 2017

S Marsh

8

1 reference

24 July 2017

A Sparreboom

9

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Clinical Pharmacology & Therapeutics

24 July 2017

published in

1 reference

24 July 2017

volume

81

1 reference

24 July 2017

issue

1

1 reference

24 July 2017

page(s)

42-49

1 reference

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

Effects of St. John's wort on irinotecan metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

Adjuvant therapy in colon cancer--what, when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Pharmacogenomics: road to anticancer therapeutics nirvana?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Molecular genetic basis of Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Role of pharmacogenetics in irinotecan therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Irinotecan pharmacogenetics: is it time to intervene?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Pharmacogenetics of irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Modulation of irinotecan metabolism by ketoconazole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Caution on pedigree haplotype inference with software that assumes linkage equilibrium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100019

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100019

1 reference

24 July 2017

1 reference